ArticleFrontiers in oncology2025
A new type of congenital hepatic hemangioma - rapid postnatal proliferation followed by regression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to analyze and summarize the prenatal and postnatal imaging findings, as well as the postnatal growth curves, of patients with hepatic hemangiomas (HHs) that were identified Methods: A retrospective study was conducted to collect and analyze data from children with congenital hepatic hemangiomas (CHH) who were diagnosed and followed-up at our hospital between January 1, 2016 and December 30, 2023. These children exhibited rapid postnatal proliferation of lesions, followed by spontaneous regression. The study recorded the patients' general clinical information, laboratory test results, and pre- and postnatal imaging characteristics of the tumor, as well as changes in tumor volume over time. Results: Eight patients (four males and four females) were included in this group, with and average gestational age of 37 weeks at the initial onset. The imaging features of this type of hepatic hemangioma are almost indistinguishable from those previously described for CHH. The only difference was that 87.5% of the tumors were located in the left lobe of the liver, and no calcification was observed within the tumors during the prenatal and proliferative stages. The postnatal growth trend of the tumors was very rapid, with complete proliferation occurring within the first six months after birth (median, 66 days) and the peak volume exceeding 1.5 × the initial volume. Of the tumors, 87.5% (7/8) regressed to 80% of the initial volume within one year, and the median time to complete regression was 365 days (range 300-730). None of the patients experienced adverse symptoms or complications during the study period. Conclusions: This article describes a special type of CHH that can continue to proliferate after birth. However, the tumor spontaneously regresses over time without complications. Therefore, for postnatal CHH growth, regular imaging observation without drug treatment or surgery is recommended, thereby preventing overtreatment while ensuring normal child development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.